logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

EHA 2020 – Cross-trial comparison shows benefit of tafasitamab in patients with diffuse large B-cell lymphomas

Will anti-CD19 activity improve responses rates in DLBCL? The answer is sought in a cross-trial comparison.